Mission Statement, Vision, & Core Values (2026) of Sumitomo Pharma Co., Ltd.

Meet Sumitomo Pharma Co., Ltd. (4506.T), a global pharmaceutical company with a legacy spanning more than 400 years that channels its heritage into cutting‑edge R&D focused on psychiatry & neurology and oncology, guided by a mission "to broadly contribute to society through value creation" and a vision "For longer and healthier lives" as it pursues the strategic aim of becoming a Global Specialized Player by 2033-a roadmap reinforced by its Mid‑term Business Plan 2027 and lived daily through core values like Patient First, Always with Integrity, and One Diverse Team that align with the UN SDGs and ambitious investment in innovative modalities to improve health outcomes worldwide.

Sumitomo Pharma Co., Ltd. (4506.T) - Intro

• Headquarters: Tokyo, Japan
• Global footprint: operations in 20+ countries and territories
• Workforce: ~10,000 employees (consolidated, FY2023)
• Strategic focus: Psychiatry & Neurology, Oncology, Specialty Care

• To contribute to the health and wellbeing of people worldwide through the creation and provision of innovative pharmaceutical products and services.
• To deliver sustainable value for patients, healthcare systems, shareholders, and society through ethical business practices and scientific excellence.

• Become a Global Specialized Player in psychiatry & neurology and oncology by 2033, with leading global franchises and differentiated pipelines.
• Achieve balanced global revenue mix with ≥50% sales outside Japan by FY2033 through international expansion, licensing, and M&A.
• Drive long-term sustainable growth with double-digit CAGR in adjusted EPS over the decade to 2033.

• Integrity - ethical decision-making, compliance, and transparent governance.
• Innovation - heavy investment in R&D, partnerships with academia and biotech, and use of digital/AI to accelerate discovery.
• Diversity & Inclusion - global talent development and cross-cultural collaboration to foster creativity.
• Patient-Centricity - prioritizing unmet medical needs, access, and real-world evidence to improve outcomes.
• Sustainability - integrating ESG into strategy, operations, and product life cycles.

• R&D spend: ~¥136.8 billion in FY2023 (~19-20% of revenue), among the highest ratios for Japanese pharma peers.
• Pipeline breadth: ~120 programs spanning small molecules, biologics, gene & cell therapy collaborations, and digital therapeutics.
• Key modalities: CNS-targeted small molecules, oncology ADCs and targeted agents, and immuno-oncology collaborations.
• External partnerships: strategic alliances with global biotech, license-ins/outs, and academic consortia to supplement internal discovery.

• SDG focus areas: Good Health & Well-Being (SDG 3), Industry, Innovation & Infrastructure (SDG 9), and Partnerships for the Goals (SDG 17).
• Environmental targets: emissions reduction roadmap (scope 1-3), energy efficiency investments in manufacturing, and progressive waste-reduction initiatives.
• Access programs: patient assistance and tiered-pricing strategies in lower-income markets; expanding clinical trial access globally.

• Revenue diversification: accelerating international sales through in-licensing, local partnerships, and expansion of specialty sales forces in Asia, Europe, and North America.
• Margin management: focus on higher-margin specialty products, lifecycle management, and operational efficiencies to improve operating margin above current levels toward mid-term targets.
• Capital allocation: prioritizing R&D and strategic M&A while maintaining disciplined balance-sheet metrics and shareholder return via dividends and share buybacks as appropriate.

• Board composition: mix of internal and independent directors with experience across pharma, finance, and global markets to strengthen oversight.
• Risk management: robust pharmacovigilance, regulatory compliance, and ESG risk integration into corporate strategy.
• Talent development: leadership programs, global rotation, and external hiring to support international growth objectives.

• Number of countries with active commercial presence: 20+
• Clinical trials ongoing: >60 active trials (Phase I-III)
• Annual new molecular entity (NME) approvals (last 5 years): 2-4 (including in-licensed approvals)
• Collaborations with major global partners: multiple licensing deals and co-development agreements in oncology and CNS

Sumitomo Pharma Co., Ltd. (4506.T) - Overview

Sumitomo Pharma Co., Ltd. (4506.T) - Mission Statement

• Core purpose: Develop and deliver transformative healthcare solutions that extend healthy lifespan and address unmet medical needs.
• Strategic horizon: Execute the Mid-term Business Plan 2027 (FY2023-FY2027) to align R&D, M&A, and commercialization for sustained innovation.
• Technology focus: Prioritize cutting-edge modalities (small molecules, biologics, gene/cell therapies, digital therapeutics) to 'unlock the future.'
• Patient-centeredity: Center research and commercialization decisions on measurable patient outcomes and quality-of-life improvements.

• 'For longer and healthier lives' - a patient- and population-level outcome metric that guides portfolio prioritization and long-term KPIs.
• 'We unlock the future' - signals proactive investment in frontier science, platform technologies, and strategic alliances to anticipate emerging health challenges.
• 'Cutting-edge technology and ideas' - communicates a commitment to both internal R&D and external innovation sourcing (academic collaborations, biotech partnerships, and in-licensing).

• R&D prioritization: Focus resources on high‑impact therapeutic areas and platform investments to support late‑stage development and launch readiness.
• Portfolio governance: Use stage-gated decision frameworks and external scientific advisory input to allocate capital efficiently.
• Commercial readiness: Build global commercialization capabilities to ensure rapid uptake and patient access upon approval.
• Sustainability & ethics: Embed compliance, ESG, and equitable access principles into corporate decision-making.

• Mid-term Business Plan 2027 serves as the operational roadmap to translate vision into measurable milestones over FY2023-FY2027.
• KPIs typically tracked include R&D advancement rates, regulatory approvals, time-to-launch, patient access metrics, and strategic alliance outcomes.
• Financial discipline and capital allocation are directed to sustain innovation while enabling global commercialization.

Sumitomo Pharma Co., Ltd. (4506.T) - Vision Statement

• Patient-centric innovation: prioritize unmet medical needs with a portfolio spanning psychiatry, oncology, regenerative medicine, and specialty therapies.
• Global reach: expand presence in North America, Europe, and Asia through M&A, alliances, and localized clinical development.
• Sustainable growth: balance near-term commercial execution with long-term pipeline investments and ethical governance.

• Patient First - prioritizing patient health and well‑being in research, development, commercialization, and post‑market support.
• Always with Integrity - conducting business with transparency, regulatory compliance, and the highest ethical standards.
• One Diverse Team - leveraging diversity of thought, experience, and culture to drive collaborative problem-solving and innovation.

• Portfolio prioritization: programs are selected based on potential patient impact, unmet need, and scientific validity rather than short‑term commercial gains.
• Clinical conduct and transparency: trial design, reporting, and pharmacovigilance follow rigorous integrity standards to protect patients and public trust.
• Organizational culture and talent: diversity initiatives, cross-border teams, and inclusion efforts aim to create a unified workforce that accelerates global execution.

• Patient First - accelerated access programs and patient support services improved adherence rates for key products by double‑digit percentages in selected markets.
• Always with Integrity - compliance and pharmacovigilance investments reduced regulatory observations and strengthened approvals across major regions.
• One Diverse Team - global R&D hubs and cross‑functional teams decreased time‑to‑first‑in‑human studies through integrated project governance.

• Targeted acquisitions and partnerships to fill pipeline gaps and bring complementary technologies (e.g., gene therapy, CNS assets).
• Incremental reinvestment of profits into R&D (R&D spend typically ~15-20% of revenue) to sustain long‑term innovation.
• Governance and ESG integration: embedding integrity and patient outcomes into executive KPIs and public disclosures.